The Human Genome Project: Benefits and Risks to Society

Abstract

The human genome project was initiated in 1990 to study the structure and characteristics of human DNA that are important for understanding gene functions and their relation to diseases. The large-scale genome research has driven the technology advancement in genetic testing, drug design, gene therapy, and other genetic related areas such as pharmacogenetics. Although the project reveals potential benefits, it raises ethical, legal, and social issues. The outcomes of individuals’ genetic information disclosure may lead to confidentiality and genetic discrimination issues. In addition, clinical relevance of genetic testing and psychological effect from the results are debatable. This article discusses the potential benefits and risks from the human genome project.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Fink L, Collins FS. The human genome project: View from the National Institutes of Health. J Am Med Worn Assoc. 1997;52(1):4–7,15.

    CAS  Google Scholar 

  2. 2.

    Cantor CR. A brief sketch of the Human Genome Project and its implications for pharmaceutical technology. Pharmaceut Tech. 1993;17:22,24,26.

    Google Scholar 

  3. 3.

    The Human Genome Project. Revised 5-year research goals of the U.S. Human Genome Project. Human Genome News. 1993;5(4):1–5.

    Google Scholar 

  4. 4.

    The Human Genome Project. Technology transfer—Commercializing genome resource. Human Genome News. 1995:7(3–4):15.

    Google Scholar 

  5. 5.

    Kadlec JV, McPherson RA. Ethical issues in screening and testing for genetic diseases. Clin Lab Med. 1995;15(4):989–999.

    CAS  Article  Google Scholar 

  6. 6.

    Ellsworth DL, Hallman DM, Boerwinkle E. Impact of the Human Genome Project of epidemiologic research. Epidemiologic Rev. 1997;19(1):3–13.

    CAS  Article  Google Scholar 

  7. 7.

    Scriver CR. Genetic screening, testing and treatment: How far can we go? J Inher Metab Dis. 1996;19:401–411.

    CAS  Article  Google Scholar 

  8. 8.

    Olopade OI. The Human Genome Project and breast cancer. Women’s Health Issues. 1997;7(4):209–214.

    CAS  Article  Google Scholar 

  9. 9.

    Mansfield BK. The Genome Project and the Pharmaceutical Industry. Human Genome News. 1990;2(4):1.

    Google Scholar 

  10. 10.

    Kelloff GJ, Hawk ET, Karp JE, Crowell JA, et al. Progress in clinical chemoprevention. Sem Oncology. 1997;24(2):241–252.

    CAS  Google Scholar 

  11. 11.

    Kalow W. Pharmacogenetics: Its place in medicine and biology. J Pharmacy Practice. 1992;6:312–316.

    Article  Google Scholar 

  12. 12.

    Hildebrand CE, Stallings RL, Torney DC, Fickett JW, et al. Human genome mapping and sequencing: Applications in Pharmaceutical Science. In: Pezzuto JM, Johnson ME, Manzsse HR, Ed. Biotechnology and Pharmacy. New York: Chapman & Hall; 1993.

    Google Scholar 

  13. 13.

    Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):417–424.

    CAS  PubMed  Google Scholar 

  14. 14.

    Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):409–415.

    CAS  PubMed  Google Scholar 

  15. 15.

    Sandhu JS, Keating A, Hozumi N. Human gene therapy. Crit Rev Biotech. 1997;17(4):307–326.

    CAS  Article  Google Scholar 

  16. 16.

    Smith TJ. Gene therapy: Opportunities for pharmacy in the 21st century. Am J Pharmaceut Educ. 1996;60:213–215.

    Google Scholar 

  17. 17.

    Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994.

    Google Scholar 

  18. 18.

    Kopala B. The Human Genome Project: Issues and ethics. Am J Maternal Child Nursing. 1997;22:9–12.

    CAS  Article  Google Scholar 

  19. 19.

    Blanck PD, Marti MW. Genetic discrimination and the employment provisions of the Americans with Disabilities Act: Emerging legal, empirical, and policy implications. Behavioral Sci Law. 1996;14:411–432.

    CAS  Article  Google Scholar 

  20. 20.

    Patenaude AF. The genetic testing of children for cancer susceptibility: Ethical, legal, and social issues. Behavioral Sci Law. 1996;14:393–410.

    CAS  Article  Google Scholar 

  21. 21.

    Wilfond BS, Noland K. National policy development for the clinical application of genetic diagnostic technologies. JAMA. 1993;270(24):2948–2954.

    CAS  Article  Google Scholar 

  22. 22.

    Cassel CK. Policy implications of the Human Genome Project for women. Women’s Health Issues. 1997;7(4):225–229.

    CAS  Article  Google Scholar 

  23. 23.

    Mahowald MB, Levinson D, Cassel C, Lemke A, et al. The new genetics and women. Milbank Quarterly. 1996;74(2):239–283.

    CAS  Article  Google Scholar 

  24. 24.

    Nsiah-Jefferson L. Reproductive genetic services for low-income women and women of color: Access and sociocultural issue. In: Rothenberg KH, Thomsom EJ, eds. Women and Prenatal Testing: Facing the Challenges of Genetic Technology. Columbus, OH: Ohio State University Press; 1994.

    Google Scholar 

  25. 25.

    Ravine D, Cooper DN. Adult-onset genetic disease: mechanisms, analysis and prediction. Q J Med. 1997;90:83–103.

    CAS  Article  Google Scholar 

  26. 26.

    Salkovskis PM, Rimes KA. Predictive genetic testing: psychological factors. J Psychosomatic Res. 1997;43(5):477–487.

    CAS  Article  Google Scholar 

  27. 27.

    Scriver CR. We mean well: Treatment of Mendelian disease. Acta Paediatr Japonica. 1988;30:385–389.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Suvara Wattanapitayakul MS.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wattanapitayakul, S., Schommer, J.C. The Human Genome Project: Benefits and Risks to Society. Ther Innov Regul Sci 33, 729–735 (1999). https://doi.org/10.1177/009286159903300310

Download citation

Key Words

  • Human genome project
  • Public policy